All articles tagged with #clinical trials
The Washington Post profiles Mark Orwig and other melanoma patients in a Moderna/M Merck trial testing an mRNA-based cancer vaccine. Early results suggest the vaccine could prevent cancer recurrence after surgery, a finding experts say could transform cancer care and accelerate FDA approval, despite participants experiencing side effects and a tough recovery.
Many patients want to join clinical trials, but recruitment is hampered by geographic, time, and cost barriers, plus limited provider referrals and difficult trial searches. While ACA-mandated coverage helps with routine trial costs, incidental expenses and out-of-network issues can block participation. Policymakers and advocacy groups are pushing to streamline rules, fund travel/childcare support, and explore decentralized trials to expand access; patients should ask about trials, use search tools, and seek navigator help to identify feasible options.
Moderna and Merck reported Phase 3 results for intismeran autogene (a personalized mRNA cancer vaccine) combined with Keytruda in high-risk melanoma patients after surgery, showing longer recurrence-free and metastasis-free survival versus Keytruda alone; safety was consistent with prior data. If confirmed, the vaccine could reshape cancer prevention and treatment and bolster mRNA vaccine credibility, but overall survival results and external validation are still pending.
A patient with an autoimmune disease died after receiving an experimental CAR-T gene therapy from a Chinese biotech startup, the third fatality in China’s controversial and opaque trials, according to Endpoints News.
A review of more than 120 randomized trials shows shorter antibiotic courses are often as effective and safer than longer ones for many common infections, challenging the long-standing guidance to always finish the full course. The findings emphasize tailored clinician–patient communication to determine duration, note that many people still prefer longer courses due to prior guidance, and warn that some infections require longer treatment; results are published in Open Forum Infectious Diseases and more than 90% of surveyed US respondents trust their doctor.
Many patients want to join clinical trials, but recruitment and participation are hindered by geographic, time, and cost barriers, and doctors often don’t raise trials. U.S. efforts to streamline rules and allow sponsors to cover travel, lodging, and other expenses aim to reduce financial disincentives, while patient navigators and decentralized trials promise easier access. Patients should ask their doctors or trial sites about eligible studies, use matching services, confirm insurance coverage and potential out-of-pocket costs, and stay alert to new, at-home or local options as trial access expands.
Early-stage studies suggest obesity drugs may help manage PMOS, a hormonal disorder, offering hope to affected families; further research is needed to confirm effectiveness and safety.
US researchers at a NIH BRAIN Initiative meeting were stunned to learn that seven Chinese trials are testing DREADDs—designer receptors activated by a designer drug—in humans to suppress targeted brain activity for conditions like epilepsy, Parkinson’s disease, and neuropathic pain. The approach uses viral delivery to express receptors in specific neurons; when the drug is administered, activity in those circuits diminishes. While potentially offering circuit-specific therapies with fewer off-target effects, gene-therapy vectors carry immune risks. A trigeminal neuropathic pain trial has the most potential, and success could open circuit-based neurotherapies for many neuropsychiatric diseases. The pace suggests China is leading in this frontier.
Erin McNulty, a long-time meth addict, becomes part of a WVU trial testing noninvasive focused ultrasound to modulate the brain’s reward center. After initial sham treatment and then real ultrasound targeting the nucleus accumbens, her cravings dropped and she maintained sobriety for months; early trial data from the first participants show large reductions in cravings and fewer positive drug tests. The approach remains experimental, with safety questions, dose variability, and the need for behavioral support, but it’s drawing interest as a potential non-surgical option to treat addiction.
A Tufts CSDD analysis of Medable's AI clinical monitoring agent finds potential ROI up to 82x and an eNPV as high as $21 million per oncology program, driven by savings from reduced site visits, faster enrollment and earlier database locks. Phase 2 ROI is about 64x, Phase 3 around 82x; direct operating savings are roughly $4.4 million (Phase 2) and $5.6 million (Phase 3). Across portfolios, the impact could reach hundreds of millions for sponsors with multiple indications, with development time shortened by about 18 weeks. Some admin savings weren’t included in the eNPV calculations.
Tufts’ Center for the Study of Drug Development finds Medable’s AI monitoring agent can speed up late-stage (phase 2/3) cancer drug trials by about 10 weeks and cut direct operating costs by up to $5.6 million, with larger net benefits as the drug targets more cancers (potentially up to $565 million for 50 indications). The technology could become standard in 3–5 years, aiding enrollment, data locking, and earlier safety assessments, while still facing challenges like patient recruitment, consent, drug distribution, and the need for human verification.
UNC Lineberger is enrolling about 2,000 North Carolinians (ages 45–75) in the Vanguard Study to evaluate blood-based, multi-cancer detection tests that could screen for several cancers at once; while promising, these assays are not FDA-approved and not yet ready for routine screening, with results guiding a larger nationwide trial and potential future changes to cancer screening.
Kalshi’s plan to let users bet on the outcomes of clinical trials has drawn sharp ethical objections from researchers and patients who warn such markets could undermine trial integrity and patient welfare, even as Kalshi argues bets would reflect updated evidence and cut through hype. The controversy highlights broader concerns about gamifying lifesaving research and treating trials as speculative bets, rather than purely scientific endeavors.
A rare human mutation in myostatin (GDF-8) removes the body's brake on muscle growth, producing infants with remarkable muscle mass and strength—cases linked to a German boy and even similar effects seen in dogs—sparking decades of research and the search for therapies that block myostatin. Yet as scientists pursued myostatin inhibitors for muscle-wasting diseases, results were largely disappointing. In 2026, a trial combining a myostatin blocker with tirzepatide for obesity showed lean-mass preservation but no clear functional gains, highlighting both the potential and the limits of applying this biology to medicine.
Mei, a six-year-old in Shanghai, received a brain-targeted CRISPR-based gene therapy for a rare neurodevelopmental disorder and died soon after the viral injection. Hospital records point to a severe immune/vascular reaction (thrombotic microangiopathy) as the likely cause, and investigators found preclinical toxicity signals were not adequately disclosed to the ethics board while the trial lacked proper public updates and dose-testing. The case underscores gaps in China’s clinical-research oversight and transparency amid intense biotech competition, reminding the field that patient safety must come before pioneering claims.